⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ELVN News
Enliven Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ELVN
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
prnewswire.com
ELVN
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
prnewswire.com
ELVN
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
globenewswire.com
ONCY
ALLO
CHRS
PYXS
ELVN
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
prnewswire.com
ELVN
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
prnewswire.com
ELVN
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
prnewswire.com
ELVN
Liver Cancer Drug Market Poised to Reach US$ 17.2 Billion by 2033 Amid Rapid Advances in Targeted Therapies | Astute Analytica
globenewswire.com
BMY
MRK
AZN
ELVN
REGN
GILD
NVS
SNY
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
prnewswire.com
ELVN
Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
prnewswire.com
ELVN